Cargando…
Lp-PLA2 Inhibition—The Atherosclerosis Panacea?
Based on the complex pathophysiology of atherosclerosis, a large number of biomarkers that relate to lipids, inflammation, immunity, thrombosis and hemostasis, have been investigated experimentally, in epidemiologic studies and in clinical trials. Interest focuses on their potential role to aid in r...
Autores principales: | Karakas, Mahir, Koenig, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033986/ https://www.ncbi.nlm.nih.gov/pubmed/27713307 http://dx.doi.org/10.3390/ph3051360 |
Ejemplares similares
-
Lp-PLA(2) Inhibitors for the Reduction of Cardiovascular Events
por: Steen, Dylan L., et al.
Publicado: (2013) -
On the present and future role of Lp-PLA(2) in atherosclerosis-related cardiovascular risk prediction and management
por: Fras, Zlatko, et al.
Publicado: (2020) -
Lp-PLA2 levels in HIV-infected patients
por: Díaz-Pollán, Beatriz, et al.
Publicado: (2014) -
Genetic invalidation of Lp-PLA(2) as a therapeutic target: Large-scale study of five functional Lp-PLA(2)-lowering alleles
por: Gregson, John M, et al.
Publicado: (2016) -
Association Lp-PLA2 Gene Polymorphisms with Coronary Heart Disease
por: Ma, Sha, et al.
Publicado: (2022)